US FDA Approves Oral Treatment for Adults with Plaque Psoriasis
The US Food and Drug Administration (FDA) has approved a new oral treatment to treat plaque psoriasis caused by Bristol Myers Squibb (BMS) after a phase 3 clinical trial. The chemical name of the drug is deucravacitinib, and it will be sold under the brand name Sotyktu. According to the National Psoriasis Foundation, around 125 […]
Continue Reading